Also on Monday, George Miller of the U.K.'s MRC Epidemiology & Medical Care Unit at St. Bartholomew's Hospital in London was to present results of the latest stage of the Northwick Park Heart study, which was expected to confirm that Shield Diagnostics' (LSE:SDG) Afecta diagnostic provides additional evidence of cardiovascular disease risk. SDG gained 35 percent 452.5p to 610p. SDG's market cap is £124.4 million (US$207 million).
Investors were also looking for positive news from Xenova (LSE:XEN; XNVAY), which this week is expected to provide clinical data from at least one of its anti-cancer compounds. XEN's third quarter results report is